References
Brown GJE, Yeomans ND. Prevention of the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: the role of proton pump inhibitors. Drug Saf 1999 Dec (6): 503–12
La Corte R, Caselli M, Castellino G, et al. Prophylaxis and treatment of NSAID-induced gastroduodenal disorders. Drug Saf 1999 Jun (6): 527–43
Wolfe MW, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. New Engl J Med 1999; 340 (24): 1888–99
Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241–9
Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of NSAID-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123: 344–50
Schoenfeld P, Kinmey MB, Scheiman J, et al. Review article: nonsteroidal anti-inflammatory drug-associated complications-guidelines for prevention and treatment. Aliment Pharmacol Ther 1999; 13: 1273–85
Yeomans ND, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 339: 719–26
Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 339: 727–34
Plosker GL, Lamb HM. Diclofenac/misoprostol. Pharmacoeconomic implications of therapy. Pharmacoeconomics 1999 Jul; 16 (1): 85–98
Rights and permissions
About this article
Cite this article
Reducing NSAID-induced gastroduodenal ulceration is possible. Drugs Ther. Perspect 15, 10–12 (2000). https://doi.org/10.2165/00042310-200015050-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200015050-00004